Ontology type: schema:ScholarlyArticle
2008-05-06
AUTHORSH. Ideguchi, S. Ohno, K. Takase, A. Ueda, Y. Ishigatsubo
ABSTRACTMost patients who switched to a second bisphosphonate continued their treatment long term, although those who stopped their first drug because of adverse events were likely to discontinue the second drug for the same reason. Switching to another bisphosphonate is a reasonable treatment option for some patients with treatment failure.IntroductionPatients who experience treatment failure with a bisphosphonate because of adverse events (AEs) or other reasons might receive a second bisphosphonate. However, the frequency and benefits of switching bisphosphonates are unknown.MethodsWe retrospectively evaluated 197 men and 1110 women newly treated with bisphosphonates between 1 January 2000 and 30 June 2005 at our university hospital.ResultsAmong the 497 patients who discontinued bisphosphonate treatment, 146 were switched to a second bisphosphonate. The cumulative probabilities of persistence of treatment after 3 years were 45% with the first bisphosphonate and 65% with the second (P = 0.017). Age ≥65 years, switching bisphosphonates because of AEs, and male gender were associated (P < 0.05) with low persistence of treatment with the second bisphosphonate. Discontinuation of the first drug because of AEs was associated with an increased rate of discontinuation of the second drug because of AEs (hazard ratio, 4.2; 95% confidence interval, 2.1–8.4).ConclusionsPatients who switched bisphosphonates had high rates of persistence of therapy. Those who stopped their first bisphosphonate because of AEs were at risk of discontinuing the second drug for the same reason. Switching to another bisphosphonate is a reasonable treatment option for some patients with treatment failure. More... »
PAGES1777-1783
http://scigraph.springernature.com/pub.10.1007/s00198-008-0618-y
DOIhttp://dx.doi.org/10.1007/s00198-008-0618-y
DIMENSIONShttps://app.dimensions.ai/details/publication/pub.1051031077
PUBMEDhttps://www.ncbi.nlm.nih.gov/pubmed/18458987
JSON-LD is the canonical representation for SciGraph data.
TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT
[
{
"@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json",
"about": [
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Medical and Health Sciences",
"type": "DefinedTerm"
},
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Clinical Sciences",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Adolescent",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Adult",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Aged",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Aged, 80 and over",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Bone Density Conservation Agents",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Diphosphonates",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Drug Administration Schedule",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Female",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Gastrointestinal Diseases",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Humans",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Male",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Medication Adherence",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Middle Aged",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Osteoporosis",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Patient Compliance",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Retrospective Studies",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Risk Assessment",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Treatment Outcome",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Young Adult",
"type": "DefinedTerm"
}
],
"author": [
{
"affiliation": {
"alternateName": "Center for Rheumatic Diseases, Yokohama City University Medical Center, 4-57 Urafune-cho, Minami-ku, 232-0024, Yokohama, Kanagawa, Japan",
"id": "http://www.grid.ac/institutes/grid.413045.7",
"name": [
"Center for Rheumatic Diseases, Yokohama City University Medical Center, 4-57 Urafune-cho, Minami-ku, 232-0024, Yokohama, Kanagawa, Japan"
],
"type": "Organization"
},
"familyName": "Ideguchi",
"givenName": "H.",
"id": "sg:person.01324761473.79",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01324761473.79"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Center for Rheumatic Diseases, Yokohama City University Medical Center, 4-57 Urafune-cho, Minami-ku, 232-0024, Yokohama, Kanagawa, Japan",
"id": "http://www.grid.ac/institutes/grid.413045.7",
"name": [
"Center for Rheumatic Diseases, Yokohama City University Medical Center, 4-57 Urafune-cho, Minami-ku, 232-0024, Yokohama, Kanagawa, Japan"
],
"type": "Organization"
},
"familyName": "Ohno",
"givenName": "S.",
"id": "sg:person.013722512012.55",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013722512012.55"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Center for Rheumatic Diseases, Yokohama City University Medical Center, 4-57 Urafune-cho, Minami-ku, 232-0024, Yokohama, Kanagawa, Japan",
"id": "http://www.grid.ac/institutes/grid.413045.7",
"name": [
"Center for Rheumatic Diseases, Yokohama City University Medical Center, 4-57 Urafune-cho, Minami-ku, 232-0024, Yokohama, Kanagawa, Japan"
],
"type": "Organization"
},
"familyName": "Takase",
"givenName": "K.",
"id": "sg:person.0756602733.05",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0756602733.05"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan",
"id": "http://www.grid.ac/institutes/grid.268441.d",
"name": [
"Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan"
],
"type": "Organization"
},
"familyName": "Ueda",
"givenName": "A.",
"id": "sg:person.01032032373.04",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01032032373.04"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan",
"id": "http://www.grid.ac/institutes/grid.268441.d",
"name": [
"Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan"
],
"type": "Organization"
},
"familyName": "Ishigatsubo",
"givenName": "Y.",
"id": "sg:person.01125133646.44",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01125133646.44"
],
"type": "Person"
}
],
"citation": [
{
"id": "sg:pub.10.1007/s00198-007-0406-0",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1013678762",
"https://doi.org/10.1007/s00198-007-0406-0"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s001980070064",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1042388661",
"https://doi.org/10.1007/s001980070064"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s00774-004-0509-z",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1010011368",
"https://doi.org/10.1007/s00774-004-0509-z"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s00198-006-0136-8",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1031571579",
"https://doi.org/10.1007/s00198-006-0136-8"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s00198-006-0322-8",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1012288373",
"https://doi.org/10.1007/s00198-006-0322-8"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s001980200135",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1033038209",
"https://doi.org/10.1007/s001980200135"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s00198-006-0179-x",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1038026469",
"https://doi.org/10.1007/s00198-006-0179-x"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s00198-006-0294-8",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1002840519",
"https://doi.org/10.1007/s00198-006-0294-8"
],
"type": "CreativeWork"
}
],
"datePublished": "2008-05-06",
"datePublishedReg": "2008-05-06",
"description": "Most patients who switched to a second bisphosphonate continued their treatment long term, although those who stopped their first drug because of adverse events were likely to discontinue the second drug for the same reason. Switching to another bisphosphonate is a reasonable treatment option for some patients with treatment failure.IntroductionPatients who experience treatment failure with a bisphosphonate because of adverse events (AEs) or other reasons might receive a second bisphosphonate. However, the frequency and benefits of switching bisphosphonates are unknown.MethodsWe retrospectively evaluated 197 men and 1110 women newly treated with bisphosphonates between 1 January 2000 and 30 June 2005 at our university hospital.ResultsAmong the 497 patients who discontinued bisphosphonate treatment, 146 were switched to a second bisphosphonate. The cumulative probabilities of persistence of treatment after 3\u00a0years were 45% with the first bisphosphonate and 65% with the second (P\u2009=\u20090.017). Age \u226565\u00a0years, switching bisphosphonates because of AEs, and male gender were associated (P\u2009<\u20090.05) with low persistence of treatment with the second bisphosphonate. Discontinuation of the first drug because of AEs was associated with an increased rate of discontinuation of the second drug because of AEs (hazard ratio, 4.2; 95% confidence interval, 2.1\u20138.4).ConclusionsPatients who switched bisphosphonates had high rates of persistence of therapy. Those who stopped their first bisphosphonate because of AEs were at risk of discontinuing the second drug for the same reason. Switching to another bisphosphonate is a reasonable treatment option for some patients with treatment failure.",
"genre": "article",
"id": "sg:pub.10.1007/s00198-008-0618-y",
"inLanguage": "en",
"isAccessibleForFree": false,
"isPartOf": [
{
"id": "sg:journal.1100834",
"issn": [
"0937-941X",
"1433-2965"
],
"name": "Osteoporosis International",
"publisher": "Springer Nature",
"type": "Periodical"
},
{
"issueNumber": "12",
"type": "PublicationIssue"
},
{
"type": "PublicationVolume",
"volumeNumber": "19"
}
],
"keywords": [
"adverse events",
"reasonable treatment option",
"treatment failure",
"second drug",
"first bisphosphonate",
"treatment options",
"University Hospital",
"first drug",
"treatment long term",
"rate of discontinuation",
"single university hospital",
"bisphosphonate treatment",
"most patients",
"male gender",
"bisphosphonates",
"patients",
"cumulative probability",
"drugs",
"discontinuation",
"hospital",
"high rate",
"treatment",
"failure",
"long term",
"IntroductionPatients",
"ConclusionsPatients",
"ResultsAmong",
"options",
"therapy",
"years",
"MethodsWe",
"women",
"persistence",
"age",
"outcomes",
"men",
"risk",
"rate",
"low persistence",
"events",
"gender",
"reasons",
"same reason",
"benefits",
"frequency",
"probability",
"terms"
],
"name": "Outcomes after switching from one bisphosphonate to another in 146 patients at a single university hospital",
"pagination": "1777-1783",
"productId": [
{
"name": "dimensions_id",
"type": "PropertyValue",
"value": [
"pub.1051031077"
]
},
{
"name": "doi",
"type": "PropertyValue",
"value": [
"10.1007/s00198-008-0618-y"
]
},
{
"name": "pubmed_id",
"type": "PropertyValue",
"value": [
"18458987"
]
}
],
"sameAs": [
"https://doi.org/10.1007/s00198-008-0618-y",
"https://app.dimensions.ai/details/publication/pub.1051031077"
],
"sdDataset": "articles",
"sdDatePublished": "2022-05-20T07:24",
"sdLicense": "https://scigraph.springernature.com/explorer/license/",
"sdPublisher": {
"name": "Springer Nature - SN SciGraph project",
"type": "Organization"
},
"sdSource": "s3://com-springernature-scigraph/baseset/20220519/entities/gbq_results/article/article_453.jsonl",
"type": "ScholarlyArticle",
"url": "https://doi.org/10.1007/s00198-008-0618-y"
}
]Download the RDF metadata as: json-ld nt turtle xml License info
JSON-LD is a popular format for linked data which is fully compatible with JSON.
curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00198-008-0618-y'
N-Triples is a line-based linked data format ideal for batch operations.
curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00198-008-0618-y'
Turtle is a human-readable linked data format.
curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00198-008-0618-y'
RDF/XML is a standard XML format for linked data.
curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00198-008-0618-y'
This table displays all metadata directly associated to this object as RDF triples.
248 TRIPLES
22 PREDICATES
100 URIs
84 LITERALS
26 BLANK NODES